Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 4Phase NA 2Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 320Leukemia, Myeloid, Acute 266Multiple Myeloma 227Carcinoma, Non-Small-Cell Lung 224Prostatic Neoplasms 202Neoplasms 196Lymphoma 191Colorectal Neoplasms 184Melanoma 179Leukemia 170Recurrence 164Pancreatic Neoplasms 163Precursor Cell Lymphoblastic Leukemia-Lymphoma 160Lung Neoplasms 150Glioblastoma 134Neoplasm Metastasis 132Lymphoma, Non-Hodgkin 128Ovarian Neoplasms 123Leukemia, Lymphocytic, Chronic, B-Cell 120Myelodysplastic Syndromes 117Lymphoma, Large B-Cell, Diffuse 110Lymphoma, Mantle-Cell 108Carcinoma, Hepatocellular 103Lymphoma, Follicular 99Stomach Neoplasms 96Carcinoma, Renal Cell 89Hodgkin Disease 88Brain Neoplasms 88Sarcoma 84Burkitt Lymphoma 75

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × Polyradiculoneuropathy, Chronic Inflammatory Demyelinating × Clear all
NCT07022197 2025-06-15

Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases

Tianjin Medical University General Hospital

Phase 1/2 Recruiting
27 enrolled

Myasthenia Gravis, Myositis, Neuromyelitis Optica, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡